Pharmacological Management of Anxiety Disorders in the Elderly

Elizabeth Crocco, Sindy Jaramillo, Caroline Cruz-Ortiz, Katherine Camfield

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Anxiety disorders are common in the elderly. Additionally, anxiety symptoms often accompany comorbid psychiatric, medical, as well as neurodegenerative diseases in the older population. Anxiety in the elderly, often accompanied by depression, can lead to worsening physical, cognitive, and functional impairments in this vulnerable population. Antidepressants are considered first-line treatment. Both selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) are efficacious and well-tolerated in the elderly. Some SSRIs are strong inhibitors of the cytochrome P450 hepatic pathway whereas others have less potential for drug interaction. Those antidepressants with more favorable pharmacokinetic profiles should be considered first-line in the treatment of anxiety. Mirtazapine and vortioxetine are also considered safe treatment options. Buspirone may have a benefit, but lacks studies in elderly populations. Although tricyclic/tetracyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) may be effective in the elderly, their side effect and safety profiles are suboptimal and thus are not recommended in late-life. Benzodiazepines and beta-blockers should generally be avoided when treating anxiety in the elderly. There is not enough evidence to support the use of antipsychotics or mood stabilizers given their risk of problems in both the long- and short-term. In addition, antipsychotics have a black box warning for increased mortality in elderly patients with dementia.

Original languageEnglish (US)
Pages (from-to)33-46
Number of pages14
JournalCurrent Treatment Options in Psychiatry
Volume4
Issue number1
DOIs
StatePublished - Mar 1 2017

Fingerprint

Anxiety Disorders
Pharmacology
Anxiety
Serotonin Uptake Inhibitors
Antidepressive Agents
Antipsychotic Agents
Drug Labeling
Buspirone
Monoamine Oxidase Inhibitors
Tricyclic Antidepressive Agents
Vulnerable Populations
Benzodiazepines
Drug Interactions
Neurodegenerative Diseases
Cytochrome P-450 Enzyme System
Population
Psychiatry
Dementia
Therapeutics
Pharmacokinetics

Keywords

  • Anxiety
  • Anxiety disorders
  • Elderly
  • Older adults
  • Selective serotonin reuptake inhibitors
  • Serotonin and norepinephrine reuptake inhibitors

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Pharmacological Management of Anxiety Disorders in the Elderly. / Crocco, Elizabeth; Jaramillo, Sindy; Cruz-Ortiz, Caroline; Camfield, Katherine.

In: Current Treatment Options in Psychiatry, Vol. 4, No. 1, 01.03.2017, p. 33-46.

Research output: Contribution to journalReview article

Crocco, Elizabeth ; Jaramillo, Sindy ; Cruz-Ortiz, Caroline ; Camfield, Katherine. / Pharmacological Management of Anxiety Disorders in the Elderly. In: Current Treatment Options in Psychiatry. 2017 ; Vol. 4, No. 1. pp. 33-46.
@article{2f7287c0428f4c9ab91bc23f1ff1da35,
title = "Pharmacological Management of Anxiety Disorders in the Elderly",
abstract = "Anxiety disorders are common in the elderly. Additionally, anxiety symptoms often accompany comorbid psychiatric, medical, as well as neurodegenerative diseases in the older population. Anxiety in the elderly, often accompanied by depression, can lead to worsening physical, cognitive, and functional impairments in this vulnerable population. Antidepressants are considered first-line treatment. Both selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) are efficacious and well-tolerated in the elderly. Some SSRIs are strong inhibitors of the cytochrome P450 hepatic pathway whereas others have less potential for drug interaction. Those antidepressants with more favorable pharmacokinetic profiles should be considered first-line in the treatment of anxiety. Mirtazapine and vortioxetine are also considered safe treatment options. Buspirone may have a benefit, but lacks studies in elderly populations. Although tricyclic/tetracyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) may be effective in the elderly, their side effect and safety profiles are suboptimal and thus are not recommended in late-life. Benzodiazepines and beta-blockers should generally be avoided when treating anxiety in the elderly. There is not enough evidence to support the use of antipsychotics or mood stabilizers given their risk of problems in both the long- and short-term. In addition, antipsychotics have a black box warning for increased mortality in elderly patients with dementia.",
keywords = "Anxiety, Anxiety disorders, Elderly, Older adults, Selective serotonin reuptake inhibitors, Serotonin and norepinephrine reuptake inhibitors",
author = "Elizabeth Crocco and Sindy Jaramillo and Caroline Cruz-Ortiz and Katherine Camfield",
year = "2017",
month = "3",
day = "1",
doi = "10.1007/s40501-017-0102-4",
language = "English (US)",
volume = "4",
pages = "33--46",
journal = "Current Treatment Options in Psychiatry",
issn = "2196-3061",
publisher = "Springer International Publishing AG",
number = "1",

}

TY - JOUR

T1 - Pharmacological Management of Anxiety Disorders in the Elderly

AU - Crocco, Elizabeth

AU - Jaramillo, Sindy

AU - Cruz-Ortiz, Caroline

AU - Camfield, Katherine

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Anxiety disorders are common in the elderly. Additionally, anxiety symptoms often accompany comorbid psychiatric, medical, as well as neurodegenerative diseases in the older population. Anxiety in the elderly, often accompanied by depression, can lead to worsening physical, cognitive, and functional impairments in this vulnerable population. Antidepressants are considered first-line treatment. Both selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) are efficacious and well-tolerated in the elderly. Some SSRIs are strong inhibitors of the cytochrome P450 hepatic pathway whereas others have less potential for drug interaction. Those antidepressants with more favorable pharmacokinetic profiles should be considered first-line in the treatment of anxiety. Mirtazapine and vortioxetine are also considered safe treatment options. Buspirone may have a benefit, but lacks studies in elderly populations. Although tricyclic/tetracyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) may be effective in the elderly, their side effect and safety profiles are suboptimal and thus are not recommended in late-life. Benzodiazepines and beta-blockers should generally be avoided when treating anxiety in the elderly. There is not enough evidence to support the use of antipsychotics or mood stabilizers given their risk of problems in both the long- and short-term. In addition, antipsychotics have a black box warning for increased mortality in elderly patients with dementia.

AB - Anxiety disorders are common in the elderly. Additionally, anxiety symptoms often accompany comorbid psychiatric, medical, as well as neurodegenerative diseases in the older population. Anxiety in the elderly, often accompanied by depression, can lead to worsening physical, cognitive, and functional impairments in this vulnerable population. Antidepressants are considered first-line treatment. Both selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) are efficacious and well-tolerated in the elderly. Some SSRIs are strong inhibitors of the cytochrome P450 hepatic pathway whereas others have less potential for drug interaction. Those antidepressants with more favorable pharmacokinetic profiles should be considered first-line in the treatment of anxiety. Mirtazapine and vortioxetine are also considered safe treatment options. Buspirone may have a benefit, but lacks studies in elderly populations. Although tricyclic/tetracyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) may be effective in the elderly, their side effect and safety profiles are suboptimal and thus are not recommended in late-life. Benzodiazepines and beta-blockers should generally be avoided when treating anxiety in the elderly. There is not enough evidence to support the use of antipsychotics or mood stabilizers given their risk of problems in both the long- and short-term. In addition, antipsychotics have a black box warning for increased mortality in elderly patients with dementia.

KW - Anxiety

KW - Anxiety disorders

KW - Elderly

KW - Older adults

KW - Selective serotonin reuptake inhibitors

KW - Serotonin and norepinephrine reuptake inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85046741678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046741678&partnerID=8YFLogxK

U2 - 10.1007/s40501-017-0102-4

DO - 10.1007/s40501-017-0102-4

M3 - Review article

VL - 4

SP - 33

EP - 46

JO - Current Treatment Options in Psychiatry

JF - Current Treatment Options in Psychiatry

SN - 2196-3061

IS - 1

ER -